Option Care Health/$OPCH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Option Care Health
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
- Ticker
- $OPCH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,397
- Headquarters
- Bannockburn, United States
- Website
- optioncarehealth.com
OPCH Metrics
BasicAdvanced
$4.8B
22.95
$1.38
0.46
-
Price and volume
Market cap
$4.8B
Beta
0.46
52-week high
$36.80
52-week low
$18.01
Average daily volume
6.4M
Financial strength
Current ratio
1.543
Quick ratio
0.982
Long term debt to equity
0.931
Total debt to equity
0.953
Interest coverage (TTM)
6.58%
Profitability
EBITDA (TTM)
411.592
Gross margin (TTM)
19.07%
Net profit margin (TTM)
3.74%
Operating margin (TTM)
5.88%
Effective tax rate (TTM)
27.15%
Revenue per employee (TTM)
$780,000
Management effectiveness
Return on assets (TTM)
6.08%
Return on equity (TTM)
16.04%
Valuation
Price to earnings (TTM)
22.947
Price to revenue (TTM)
0.851
Price to book
3.59
Price to tangible book (TTM)
-8.43
Price to free cash flow (TTM)
17.381
Free cash flow yield (TTM)
5.75%
Free cash flow per share (TTM)
1.824
Growth
Revenue change (TTM)
4.01%
Earnings per share change (TTM)
8.82%
3-year revenue growth (CAGR)
11.01%
3-year earnings per share growth (CAGR)
-0.87%
What the Analysts think about OPCH
Analyst ratings (Buy, Hold, Sell) for Option Care Health stock.
Analyst projections of the future price of Option Care Health stock.
Bulls say / Bears say
CD&R and McKesson have agreed to buy Option Care for $32.05 per share in cash, a 37% premium to the 5 October closing price. If shareholders and regulators approve the deal, it gives investors a defined cash exit. (Option Care Health, Inc.)
Second-quarter adjusted EBITDA rose 3% and adjusted EPS rose 12.9% year on year, while operating cash flow reached $184 million. The results suggest operations improved after a weaker first quarter. (Option Care Health, Inc.)
The acute therapy portfolio grew at a high-single-digit rate in the second quarter, while IG/neuro and rare-and-orphan therapies also grew. These areas offer growth beyond the weaker chronic inflammatory portfolio. (U.S. Securities and Exchange Commission)
Management expects chronic inflammatory disease headwinds to reduce 2026 revenue growth by about six percentage points and gross profit by $55 million. Patient attrition and a less favourable therapy mix make a near-term recovery uncertain. (Option Care Health, Inc.)
Revenue grew only 1.6% in the first half, while gross profit fell from a year earlier. Deutsche Bank also questioned whether cost cuts can compensate for weak underlying gross-profit growth. (U.S. Securities and Exchange Commission, Investing.com)
Insurance and formulary changes doubled the number of patients needing benefit rechecks and reauthorisation in the first quarter, delaying decisions and worsening retention. Such payer-driven disruptions could continue to unsettle patient volumes. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
OPCH Financial Performance
Revenues and expenses
OPCH Earnings Performance
Company profitability
Upcoming events
No upcoming events
OPCH News
AllArticlesVideos

Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc. - OPCH
Business Wire11 minutes ago

OPCH Stock Alert: Halper Sadeh LLC is Investigating Whether Option Care Health, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire2 weeks ago

OPCH Investors Have Opportunity to Join Option Care Health, Inc. Fraud Investigation with SBS Law
Business Wire1 month ago
Funds containing OPCH
Fund name | Fund size | $OPCH weighting |
|---|---|---|
iShares Ageing Population$AGED | $887M | 0.41% |
iShares Ageing Population£AGES | $887M | 0.41% |
iShares Ageing Population€AGED | $887M | 0.41% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.17% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.